Kazuhiro Noguchi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kazuhiro Noguchi has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Rie Kuroda
Kanazawa University Hospital
7 shared publications- Yasuhiro Ikawa
Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University 7 Department of Pediatrics School of Medicine Kanazawa
7 shared publications Taizo Wada
Kanazawa University Hospital
5 shared publications- Toshihiro Fujiki
Department of Pediatrics, Kanazawa University, Kanazawa, Ishikawa, Japan
5 shared publications Mika Takenaka
Kanazawa University Hospital
4 shared publicationsYuta Sakai
Kanazawa University Hospital
4 shared publications
Latest Publications
- Open Access
- 31 January 2024
- Published by Wiley
Presence of identical B-cell clone in both cerebrospinal fluid and tumor tissue in a patient with Opsoclonus-myoclonus syndrome associated with neuroblastoma
Opsoclonus-myoclonus syndrome associated with neuroblastoma (OMS-NB) is a refractory paraneoplastic syndrome which often remain neurological sequelae, and detailed pathogenesis has remained elusive. We encountered a pediatric patient with OMS-NB treated by immunosuppressed therapy who showed anti-glutamate receptor δ2 antibody and increased B-cells in cerebrospinal fluid (CSF), and multiple lymphoid follicles containing abundant B-cells in tumor tissue. Unbiased B-cell receptor repertoire analysis revealed identical B-cell clone was identified as the dominant clone in both CSF and tumor tissue. These identical B-cell clone may contribute to the pathogenesis of OMS-NB. Our results could facilitate the establishment of pathogenesis-based treatment strategies for OMS-NB.
- 31 January 2024
- Published by Wiley
Open AccessPresence of identical B-cell clone in both cerebrospinal fluid and tumor tissue in a patient with Opsoclonus-myoclonus syndrome associated with neuroblastoma
Opsoclonus-myoclonus syndrome associated with neuroblastoma (OMS-NB) is a refractory paraneoplastic syndrome which often remain neurological sequelae, and detailed pathogenesis has remained elusive. We encountered a pediatric patient with OMS-NB treated by immunosuppressed therapy who showed anti-glutamate receptor δ2 antibody and increased B-cells in cerebrospinal fluid (CSF), and multiple lymphoid follicles containing abundant B-cells in tumor tissue. Unbiased B-cell receptor repertoire analysis revealed identical B-cell clone was identified as the dominant clone in both CSF and tumor tissue. These identical B-cell clone may contribute to the pathogenesis of OMS-NB. Our results could facilitate the establishment of pathogenesis-based treatment strategies for OMS-NB.
- Open Access
Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review
Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) is an aggressive T-cell lymphoma characterized by large T-cells with strong CD30 and ALK expression. Although conventional chemotherapy is effective in most patients, approximately 30% experience a relapse or refractory disease and have a poor prognosis. Several risk factors associated with poor prognosis have been identified in pediatric ALK-positive ALCL. These include morphological patterns with the small cell variant or lymphohistiocytic variant, leukemic presentation, the presence of minimal disseminated disease, or involvement of the central nervous system. Relapsed or refractory ALK-positive ALCL is often resistant to conventional chemotherapy; therefore, salvage therapy is required. In recent years, targeted therapies such as ALK inhibitors and brentuximab vedotin (BV) have been developed. ALK inhibitors block the continuous activation of ALK kinase, a driver mutation that leads to cell proliferation in ALK-positive ALCL. Additionally, BV is an antibody–drug conjugate that targets CD30-positive cells. Both ALK inhibitors and BV have displayed dramatic effects in chemoresistant ALK-positive ALCL. Weekly vinblastine treatment and hematopoietic stem cell transplantation have also been reported to be effective therapies. This article reviews pediatric ALK-positive ALCL, focusing on risk factors and treatment strategies for pediatric patients with relapsed or refractory ALK-positive ALCL.
Open AccessStrategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review
Anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) is an aggressive T-cell lymphoma characterized by large T-cells with strong CD30 and ALK expression. Although conventional chemotherapy is effective in most patients, approximately 30% experience a relapse or refractory disease and have a poor prognosis. Several risk factors associated with poor prognosis have been identified in pediatric ALK-positive ALCL. These include morphological patterns with the small cell variant or lymphohistiocytic variant, leukemic presentation, the presence of minimal disseminated disease, or involvement of the central nervous system. Relapsed or refractory ALK-positive ALCL is often resistant to conventional chemotherapy; therefore, salvage therapy is required. In recent years, targeted therapies such as ALK inhibitors and brentuximab vedotin (BV) have been developed. ALK inhibitors block the continuous activation of ALK kinase, a driver mutation that leads to cell proliferation in ALK-positive ALCL. Additionally, BV is an antibody–drug conjugate that targets CD30-positive cells. Both ALK inhibitors and BV have displayed dramatic effects in chemoresistant ALK-positive ALCL. Weekly vinblastine treatment and hematopoietic stem cell transplantation have also been reported to be effective therapies. This article reviews pediatric ALK-positive ALCL, focusing on risk factors and treatment strategies for pediatric patients with relapsed or refractory ALK-positive ALCL.
- 12 January 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (4) , e30172
Pediatric inflammatory myofibroblastic tumor of the bladder with ALK–FN1 fusion successfully treated by alectinib
An inflammatory myofibroblastic tumor (IMT) is a mesenchymal neoplasm characterized by the proliferation of myofibroblasts and inflammatory cell infiltration. Although radical resection is the only established treatment strategy for IMT, it can cause functional disorders when vital organs are affected. We describe a case of pediatric IMT of the bladder with FN1–ALK (fibronectin 1–anaplastic lymphoma kinase) fusion. Radical resection might lead to urinary disturbance due to the large tumor size at diagnosis. However, the tumor was successfully treated with alectinib, a second‐generation ALK inhibitor, followed by transurethral resection of the bladder tumor without any complications.
- 12 January 2023
- Published by Wiley in Pediatric Blood & Cancer
- Vol. 70 (4) , e30172
Pediatric inflammatory myofibroblastic tumor of the bladder with ALK–FN1 fusion successfully treated by alectinib
An inflammatory myofibroblastic tumor (IMT) is a mesenchymal neoplasm characterized by the proliferation of myofibroblasts and inflammatory cell infiltration. Although radical resection is the only established treatment strategy for IMT, it can cause functional disorders when vital organs are affected. We describe a case of pediatric IMT of the bladder with FN1–ALK (fibronectin 1–anaplastic lymphoma kinase) fusion. Radical resection might lead to urinary disturbance due to the large tumor size at diagnosis. However, the tumor was successfully treated with alectinib, a second‐generation ALK inhibitor, followed by transurethral resection of the bladder tumor without any complications.
- Open Access
- 1 October 2021
- Published by Elsevier in Journal of Pediatric Surgery Case Reports
- Vol. 73
Neuroblastoma with ovarian and pancreatic metastasis
- 1 October 2021
- Published by Elsevier in Journal of Pediatric Surgery Case Reports
- Vol. 73
Open AccessNeuroblastoma with ovarian and pancreatic metastasis
- Open Access
- 22 August 2021
- Published by Wiley in British Journal of Haematology
- Vol. 196 (1) , 241-243
Characterisation of two tumour cell populations in the small cell variant of anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma
- 22 August 2021
- Published by Wiley in British Journal of Haematology
- Vol. 196 (1) , 241-243
Open AccessCharacterisation of two tumour cell populations in the small cell variant of anaplastic lymphoma kinase‐positive anaplastic large cell lymphoma
- Open Access
- 25 November 2020
- Published by Wiley
High-dose methotrexate-induced acral erythema in two pediatric patients with acute lymphoblastic leukemia: a 17 pediatric case series of methotrexate induced acral erythema
High-dose methotrexate-induced acral erythema in two pediatric patients with acute lymphoblastic leukemia: a 17 pediatric case series of methotrexate induced acral erythemaKazuhiro Noguchi,1 Ryosei Nishimura,1* Yasuhiro Ikawa,1Shintaro Mase,1 Toshihiro Fujiki,1Rie Kuroda,1 Raita Araki,1 Hideaki Maeba,1 Akihiro Yachie1 and Taizo Wada1
- 25 November 2020
- Published by Wiley
Open AccessHigh-dose methotrexate-induced acral erythema in two pediatric patients with acute lymphoblastic leukemia: a 17 pediatric case series of methotrexate induced acral erythema
High-dose methotrexate-induced acral erythema in two pediatric patients with acute lymphoblastic leukemia: a 17 pediatric case series of methotrexate induced acral erythemaKazuhiro Noguchi,1 Ryosei Nishimura,1* Yasuhiro Ikawa,1Shintaro Mase,1 Toshihiro Fujiki,1Rie Kuroda,1 Raita Araki,1 Hideaki Maeba,1 Akihiro Yachie1 and Taizo Wada1
- 19 April 2017
- Published by SPIE-Intl Soc Optical Eng
- Vol. 10169, 101692X-101692X-6
On impedance measurement of reinforced concrete on the surface for estimate of corroded rebar
- 19 April 2017
- Published by SPIE-Intl Soc Optical Eng
- Vol. 10169, 101692X-101692X-6
On impedance measurement of reinforced concrete on the surface for estimate of corroded rebar
- 10 August 1991
- Published by Optica Publishing Group in Applied Optics
- Vol. 30 (23) , 3277-3278
Two-dimensional multichannel optical switch
Optics InfoBase is the Optical Society's online library for flagship journals, partnered and copublished journals, and recent proceedings from OSA conferences.
- 10 August 1991
- Published by Optica Publishing Group in Applied Optics
- Vol. 30 (23) , 3277-3278
Two-dimensional multichannel optical switch
Optics InfoBase is the Optical Society's online library for flagship journals, partnered and copublished journals, and recent proceedings from OSA conferences.